Seshadri Vishwas 4

What Happened

• Seshadri Vishwas, Chief Executive Officer of Abeona Therapeutics, sold 29,985 shares of ABEO in an open-market transaction on March 31, 2026. The weighted-average price reported was $4.38 per share, for total proceeds of approximately $131,481.
• This transaction is a sale (S) and, as with most insider sales, is a distribution of holdings rather than a direct bullish signal from management.

Key Details

• Transaction date: 2026-03-31.
• Shares sold: 29,985; weighted-average price: $4.38; total proceeds: $131,481.
• Price range and breakdown: shares were sold in multiple trades at prices from $4.31 to $4.43; the filing says the reporting person will provide a per-price breakdown on request (footnote).
• Plan disclosure: sale executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Vishwas on September 17, 2024 (footnote).
• Shares owned after transaction: not reported in the provided summary of the filing.
• Filing timeliness: transaction and filing dates are both 2026-03-31, indicating a timely Form 4 filing.

Context

• 10b5-1 plans are pre-arranged trading programs that allow insiders to sell shares at predetermined times and are generally considered routine; they reduce concerns about trading on contemporaneous, nonpublic information but do not indicate the insider’s current view of the company.
• For retail investors, purchases typically carry more informational weight than routine sales; this transaction should be viewed as a planned disposition under a trading plan rather than an explicit judgment on the company’s prospects.